{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:09:48Z","timestamp":1785283788145,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Ministry of Health, Labour and Welfare Research, Japan","award":["23FC1058"],"award-info":[{"award-number":["23FC1058"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-025-01976-7","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T11:02:26Z","timestamp":1739962946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The effect of calcitonin gene-related peptide monoclonal antibodies on restless legs syndrome in patients with migraine"],"prefix":"10.1186","volume":"26","author":[{"given":"Keisuke","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saro","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukuto","family":"Shioda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Hida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"issue":"1","key":"1976_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11940-009-0056-y","volume":"12","author":"JC Rains","year":"2010","unstructured":"Rains JC, Poceta JS (2010) Sleep and headache. Curr Treat Options Neurol 12(1):1\u201315. https:\/\/doi.org\/10.1007\/s11940-009-0056-y","journal-title":"Curr Treat Options Neurol"},{"issue":"1","key":"1976_CR2","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s10194-020-01192-5","volume":"21","author":"C Tiseo","year":"2020","unstructured":"Tiseo C, Vacca A, Felbush A, Filimonova T, Gai A, Glazyrina T, Hubalek IA, Marchenko Y, Overeem LH, Piroso S, Tkachev A, Martelletti P, Sacco S, European Headache Federation School of Advanced S (2020) Migraine and sleep disorders: a systematic review. J Headache Pain 21(1):126. https:\/\/doi.org\/10.1186\/s10194-020-01192-5","journal-title":"J Headache Pain"},{"key":"1976_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s41105-024-00547-8","author":"K Suzuki","year":"2024","unstructured":"Suzuki K, Suzuki S, Haruyama Y, Fujita H, Hirata K (2024) Clinical impact of restless legs syndrome in patients with migraine: a 12-year, single-center, longitudinal study. Sleep Biol Rhythms. https:\/\/doi.org\/10.1007\/s41105-024-00547-8","journal-title":"Sleep Biol Rhythms"},{"issue":"2","key":"1976_CR4","doi-asserted-by":"publisher","first-page":"e16106","DOI":"10.1111\/ene.16106","volume":"31","author":"S de Vries Lentsch","year":"2024","unstructured":"de Vries Lentsch S, van der Arend BWH, de Boer I, van Zwet EW, MaassenVanDenBrink A, Terwindt GM (2024) Depression and treatment with anti-calcitonin gene related peptide (CGRP) (ligand or receptor) antibodies for migraine. Eur J Neurol 31(2):e16106. https:\/\/doi.org\/10.1111\/ene.16106","journal-title":"Eur J Neurol"},{"issue":"13","key":"1976_CR5","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1177\/03331024221111526","volume":"42","author":"LF Iannone","year":"2022","unstructured":"Iannone LF, De Cesaris F, Ferrari A, Benemei S, Fattori D, Chiarugi A (2022) Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine. Cephalalgia 42(13):1323\u20131330. https:\/\/doi.org\/10.1177\/03331024221111526","journal-title":"Cephalalgia"},{"key":"1976_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.sleep.2024.03.026","volume":"117","author":"G Viticchi","year":"2024","unstructured":"Viticchi G, Di Stefano V, Altamura C, Falsetti L, Torrente A, Brunelli N, Salvemini S, Alonge P, Bartolini M, Di Felice C, Adragna MS, Moroncini G, Vernieri F, Brighina F, Silvestrini M (2024) Effects of prophylactic drug therapies and anti-calcitonin peptide-related monoclonal antibodies on subjective sleep quality: an Italian multicenter study. Sleep Med 117:87\u201394. https:\/\/doi.org\/10.1016\/j.sleep.2024.03.026","journal-title":"Sleep Med"},{"key":"1976_CR7","doi-asserted-by":"publisher","first-page":"120462","DOI":"10.1016\/j.jns.2022.120462","volume":"443","author":"S Suzuki","year":"2022","unstructured":"Suzuki S, Suzuki K, Shiina T, Kobayashi S, Hirata K (2022) Can calcitonin gene-related peptide monoclonal antibody improve migraine and restless legs syndrome? J Neurol Sci 443:120462. https:\/\/doi.org\/10.1016\/j.jns.2022.120462","journal-title":"J Neurol Sci"},{"issue":"11\u201312","key":"1976_CR8","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1177\/03331024211017879","volume":"41","author":"V Gonzalez-Quintanilla","year":"2021","unstructured":"Gonzalez-Quintanilla V, Perez-Pereda S, Gonzalez-Suarez A, Madera J, Toriello M, Pascual J (2021) Restless legs-like syndrome as an emergent adverse event of CGRP monoclonal antibodies: a report of two cases. Cephalalgia 41(11\u201312):1272\u20131275. https:\/\/doi.org\/10.1177\/03331024211017879","journal-title":"Cephalalgia"},{"key":"1976_CR9","doi-asserted-by":"publisher","unstructured":"Headache_Classification_Committee_of_the_International_Headache_Society_(IHS) (2018) The International classification of Headache disorders, 3rd edition. Cephalalgia 38(1):1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"issue":"5","key":"1976_CR10","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1212\/WNL.53.5.988","volume":"53","author":"WF Stewart","year":"1999","unstructured":"Stewart WF, Lipton RB, Whyte J, Dowson A, Kolodner K, Liberman JN, Sawyer J (1999) An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 53(5):988\u2013994","journal-title":"Neurology"},{"issue":"12","key":"1976_CR11","doi-asserted-by":"publisher","first-page":"e0188719","DOI":"10.1371\/journal.pone.0188719","volume":"12","author":"K Tanaka","year":"2017","unstructured":"Tanaka K, Nishigami T, Mibu A, Manfuku M, Yono S, Shinohara Y, Tanabe A, Ono R (2017) Validation of the Japanese version of the Central Sensitization Inventory in patients with musculoskeletal disorders. PLoS ONE 12(12):e0188719. https:\/\/doi.org\/10.1371\/journal.pone.0188719","journal-title":"PLoS ONE"},{"issue":"8","key":"1976_CR12","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.sleep.2014.03.025","volume":"15","author":"RP Allen","year":"2014","unstructured":"Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman JW, Zucconi M, Ferri R, Trenkwalder C, Lee HB, International Restless Legs Syndrome Study G (2014) Restless legs syndrome\/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria\u2013history, rationale, description, and significance. Sleep Med 15(8):860\u2013873. https:\/\/doi.org\/10.1016\/j.sleep.2014.03.025","journal-title":"Sleep Med"},{"issue":"2","key":"1976_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/s1389-9457(02)00258-7","volume":"4","author":"AS Walters","year":"2003","unstructured":"Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, Trenkwalder C, International Restless Legs Syndrome Study G (2003) Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 4(2):121\u2013132. https:\/\/doi.org\/10.1016\/s1389-9457(02)00258-7","journal-title":"Sleep Med"},{"key":"1976_CR14","doi-asserted-by":"crossref","unstructured":"Kohnen R, Roth T, Grieger F, Moran K, Ondo W (2013) Determination of the minimal clinically important improvement in IRLS total score in patients with moderate to severe restless legs syndrome treated with Rotigotine Transdermal System: a Post Hoc Analysis from a 6-Month Placebo-controlled European study (P02. 056). AAN Enterprises","DOI":"10.1212\/WNL.80.7_supplement.P02.056"},{"issue":"11","key":"1976_CR15","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.sleep.2013.08.001","volume":"14","author":"RP Allen","year":"2013","unstructured":"Allen RP (2013) Minimal clinically significant change for the International Restless Legs Syndrome Study Group rating scale in clinical trials is a score of 3. Sleep Med 14(11):1229. https:\/\/doi.org\/10.1016\/j.sleep.2013.08.001","journal-title":"Sleep Med"},{"issue":"1","key":"1976_CR16","doi-asserted-by":"publisher","first-page":"6921","DOI":"10.1038\/s41598-022-10883-9","volume":"12","author":"CG Park","year":"2022","unstructured":"Park CG, Chu MK (2022) Interictal plasma glutamate levels are elevated in individuals with episodic and chronic migraine. Sci Rep 12(1):6921. https:\/\/doi.org\/10.1038\/s41598-022-10883-9","journal-title":"Sci Rep"},{"issue":"8","key":"1976_CR17","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1177\/03331024221077665","volume":"42","author":"J Thuraiaiyah","year":"2022","unstructured":"Thuraiaiyah J, Kokoti L, Al-Karagholi MA, Ashina M (2022) Involvement of adenosine signaling pathway in migraine pathophysiology: a systematic review of clinical studies. Cephalalgia 42(8):781\u2013792. https:\/\/doi.org\/10.1177\/03331024221077665","journal-title":"Cephalalgia"},{"key":"1976_CR18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.sleep.2019.01.027","volume":"57","author":"J Wang","year":"2019","unstructured":"Wang J, Gao Y, Liu L, Xu W, Zhang P, Liu Y, Qian X, Yu S (2019) The association between migraine and restless legs syndrome: an updated systematic review and meta-analysis. Sleep Med 57:21\u201329. https:\/\/doi.org\/10.1016\/j.sleep.2019.01.027","journal-title":"Sleep Med"},{"issue":"3","key":"1976_CR19","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1177\/0333102417736900","volume":"39","author":"L Edvinsson","year":"2019","unstructured":"Edvinsson L, Warfvinge K (2019) Recognizing the role of CGRP and CGRP receptors in migraine and its treatment. Cephalalgia 39(3):366\u2013373. https:\/\/doi.org\/10.1177\/0333102417736900","journal-title":"Cephalalgia"},{"issue":"40","key":"1976_CR20","doi-asserted-by":"publisher","first-page":"12532","DOI":"10.1523\/JNEUROSCI.2887-09.2009","volume":"29","author":"AR Charbit","year":"2009","unstructured":"Charbit AR, Akerman S, Holland PR, Goadsby PJ (2009) Neurons of the dopaminergic\/calcitonin gene-related peptide A11 cell group modulate neuronal firing in the trigeminocervical complex: an electrophysiological and immunohistochemical study. J Neurosci 29(40):12532\u201312541. https:\/\/doi.org\/10.1523\/JNEUROSCI.2887-09.2009","journal-title":"J Neurosci"},{"key":"1976_CR21","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.neuroscience.2015.01.062","volume":"291","author":"CM Barry","year":"2015","unstructured":"Barry CM, Kestell G, Gillan M, Haberberger RV, Gibbins IL (2015) Sensory nerve fibers containing calcitonin gene-related peptide in gastrocnemius, latissimus dorsi and erector spinae muscles and thoracolumbar fascia in mice. Neuroscience 291:106\u2013117. https:\/\/doi.org\/10.1016\/j.neuroscience.2015.01.062","journal-title":"Neuroscience"},{"issue":"2","key":"1976_CR22","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1152\/physrev.00059.2021","volume":"103","author":"AF Russo","year":"2023","unstructured":"Russo AF, Hay DL (2023) CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond. Physiol Rev 103(2):1565\u20131644. https:\/\/doi.org\/10.1152\/physrev.00059.2021","journal-title":"Physiol Rev"},{"issue":"27","key":"1976_CR23","doi-asserted-by":"publisher","first-page":"24994","DOI":"10.1074\/jbc.M211379200","volume":"278","author":"SG Rossi","year":"2003","unstructured":"Rossi SG, Dickerson IM, Rotundo RL (2003) Localization of the calcitonin gene-related peptide receptor complex at the vertebrate neuromuscular junction and its role in regulating acetylcholinesterase expression. J Biol Chem 278(27):24994\u201325000. https:\/\/doi.org\/10.1074\/jbc.M211379200","journal-title":"J Biol Chem"},{"issue":"2","key":"1976_CR24","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1113\/JP275341","volume":"597","author":"D Czesnik","year":"2019","unstructured":"Czesnik D, Howells J, Bartl M, Veiz E, Ketzler R, Kemmet O, Walters AS, Trenkwalder C, Burke D, Paulus W (2019) I(h) contributes to increased motoneuron excitability in restless legs syndrome. J Physiol 597(2):599\u2013609. https:\/\/doi.org\/10.1113\/JP275341","journal-title":"J Physiol"},{"issue":"10","key":"1976_CR25","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1177\/0333102419844711","volume":"39","author":"KW Johnson","year":"2019","unstructured":"Johnson KW, Morin SM, Wroblewski VJ, Johnson MP (2019) Peripheral and central nervous system distribution of the CGRP neutralizing antibody [(125)I] galcanezumab in male rats. Cephalalgia 39(10):1241\u20131248. https:\/\/doi.org\/10.1177\/0333102419844711","journal-title":"Cephalalgia"},{"issue":"1","key":"1976_CR26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1212\/01.wnl.0000223316.53428.c9","volume":"67","author":"S Clemens","year":"2006","unstructured":"Clemens S, Rye D, Hochman S (2006) Restless legs syndrome: revisiting the dopamine hypothesis from the spinal cord perspective. Neurology 67(1):125\u2013130. https:\/\/doi.org\/10.1212\/01.wnl.0000223316.53428.c9","journal-title":"Neurology"},{"issue":"3","key":"1976_CR27","doi-asserted-by":"publisher","first-page":"275","DOI":"10.5664\/jcsm.26585","volume":"2","author":"JS Rotenberg","year":"2006","unstructured":"Rotenberg JS, Canard K, Difazio M (2006) Successful treatment of recalcitrant restless legs syndrome with botulinum toxin type-A. J Clin Sleep Med 2(3):275\u2013278","journal-title":"J Clin Sleep Med"},{"key":"1976_CR28","doi-asserted-by":"publisher","unstructured":"Luvisetto S (2021) Botulinum neurotoxins in Central Nervous System: an overview from animal models to human therapy. Toxins (Basel) 13(11). https:\/\/doi.org\/10.3390\/toxins13110751","DOI":"10.3390\/toxins13110751"},{"issue":"20","key":"1976_CR29","doi-asserted-by":"publisher","first-page":"e2794","DOI":"10.1212\/WNL.0000000000010740","volume":"95","author":"C Ziegeler","year":"2020","unstructured":"Ziegeler C, Mehnert J, Asmussen K, May A (2020) Central effects of erenumab in migraine patients: an event-related functional imaging study. Neurology 95(20):e2794\u2013e2802. https:\/\/doi.org\/10.1212\/WNL.0000000000010740","journal-title":"Neurology"},{"issue":"4","key":"1976_CR30","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s00415-020-10295-7","volume":"268","author":"K Suzuki","year":"2021","unstructured":"Suzuki K, Suzuki S, Haruyama Y, Okamura M, Shiina T, Fujita H, Kobashi G, Sairenchi T, Uchiyama K, Hirata K (2021) Central sensitization in migraine is related to restless legs syndrome. J Neurol 268(4):1395\u20131401. https:\/\/doi.org\/10.1007\/s00415-020-10295-7","journal-title":"J Neurol"},{"issue":"1","key":"1976_CR31","doi-asserted-by":"publisher","first-page":"21824","DOI":"10.1038\/s41598-024-72282-6","volume":"14","author":"D Danno","year":"2024","unstructured":"Danno D, Imai N, Kitamura S, Ishizaki K, Kikui S, Takeshima T (2024) Efficacy of galcanezumab in migraine central sensitization. Sci Rep 14(1):21824. https:\/\/doi.org\/10.1038\/s41598-024-72282-6","journal-title":"Sci Rep"},{"key":"1976_CR32","doi-asserted-by":"publisher","first-page":"103531","DOI":"10.1016\/j.nicl.2023.103531","volume":"40","author":"E Szabo","year":"2023","unstructured":"Szabo E, Ashina S, Melo-Carrillo A, Bolo NR, Borsook D, Burstein R (2023) Peripherally acting anti-CGRP monoclonal antibodies alter cortical gray matter thickness in migraine patients: a prospective cohort study. Neuroimage Clin 40:103531. https:\/\/doi.org\/10.1016\/j.nicl.2023.103531","journal-title":"Neuroimage Clin"},{"key":"1976_CR33","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.2147\/JPR.S329280","volume":"15","author":"K Suzuki","year":"2022","unstructured":"Suzuki K, Suzuki S, Shiina T, Kobayashi S, Hirata K (2022) Central Sensitization in Migraine: a narrative review. J Pain Res 15:2673\u20132682. https:\/\/doi.org\/10.2147\/JPR.S329280","journal-title":"J Pain Res"},{"key":"1976_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.smrv.2019.05.005","volume":"47","author":"C Dafkin","year":"2019","unstructured":"Dafkin C, McKinon W, Kerr S (2019) Restless legs syndrome: clinical changes in nervous system excitability at the spinal cord level. Sleep Med Rev 47:9\u201317. https:\/\/doi.org\/10.1016\/j.smrv.2019.05.005","journal-title":"Sleep Med Rev"},{"issue":"6","key":"1976_CR35","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/j.1468-2982.2008.01550.x","volume":"28","author":"JH Kim","year":"2008","unstructured":"Kim JH, Suh SI, Seol HY, Oh K, Seo WK, Yu SW, Park KW, Koh SB (2008) Regional grey matter changes in patients with migraine: a voxel-based morphometry study. Cephalalgia 28(6):598\u2013604. https:\/\/doi.org\/10.1111\/j.1468-2982.2008.01550.x","journal-title":"Cephalalgia"},{"issue":"12","key":"1976_CR36","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/mds.21608","volume":"22","author":"A Unrath","year":"2007","unstructured":"Unrath A, Juengling FD, Schork M, Kassubek J (2007) Cortical grey matter alterations in idiopathic restless legs syndrome: an optimized voxel-based morphometry study. Mov Disord 22(12):1751\u20131756. https:\/\/doi.org\/10.1002\/mds.21608","journal-title":"Mov Disord"},{"issue":"1","key":"1976_CR37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/acn3.680","volume":"6","author":"FC Yang","year":"2019","unstructured":"Yang FC, Chou KH, Lee PL, Yin JH, Chen SY, Kao HW, Sung YF, Chou CH, Tsai CK, Tsai CL, Lin CP, Lee JT (2019) Patterns of gray matter alterations in migraine and restless legs syndrome. Ann Clin Transl Neurol 6(1):57\u201367. https:\/\/doi.org\/10.1002\/acn3.680","journal-title":"Ann Clin Transl Neurol"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-01976-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-01976-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-01976-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T11:02:32Z","timestamp":1739962952000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-025-01976-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1976"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-01976-7","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in compliance with the principles of the Declaration of Helsinki and was approved by the Institutional Review Board of Dokkyo Medical University Hospital (approval number: R-89\u20131\u00a0J). The Institutional Review Board of Dokkyo Medical University Hospital waived the requirement for patients to sign informed consent forms on the basis of the retrospective, observational nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare the following potential conflicts of interest with respect to the research, authorship, and\/or publication of this article. K Suzuki received lecture fees from Eli Lilly Japan, Daiichi Sankyo and Otsuka Pharmaceutical Co., Ltd., during the study. S Suzuki received lecture fees from Eli Lilly Japan, Daiichi Sankyo, Amgen and Otsuka Pharmaceutical Co., Ltd., during the study. H Fujita, S Kobayashi, M Shioda and R Hida have nothing to disclose. K Hirata received lecture fees from Eli Lilly Japan, Daiichi Sankyo, Amgen and Otsuka Pharmaceutical Co., Ltd., during the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}